Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04073160
Title TRIO Bladder: A Phase Ib Study of Durvalumab (MEDI 4736) Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation, Based on Molecular Subtypes in Muscle-Invasive Bladder Cancer (TRIO Bladder)
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements No
Sponsors Daniel George, MD
Indications

bladder urothelial carcinoma

Therapies

Durvalumab

Durvalumab + Tremelimumab

Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Duke University Medical Center Durham North Carolina 27710 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field